UroToday.com· @urotoday · X·· 5 小时前评分45
正文 · 原文
HRQoL After Induction Ipilimumab + Nivolumab and Bladder-Sparing Chemoradiotherapy in #MIBC: Phase 2 INDIBLADE Trial. Presented by Jan-Jaap Mellema @NKI_nl. #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4yMMinJ #BladderCancer #Immunotherapy @myESMO
86 浏览 · 2 赞 · 1 转发 · 0 回复
会议摘要
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.org来源：UroToday.com · x.com